4 ms·
This is to be expected. The big issue is that it is not worth it for a pharmaceutical company to develop new antibiotics. The initial cost is high. Then, if it
by RcouF1uZ4gsC 10y ago
This is to be expected. The big issue is that it is not worth it for a pharmaceutical company to develop new antibiotics. The initial cost is high. Then, if it is successful, the antibiotic will only be given as a last resort, thus reducing the number of doses. In addition, unlike chronic conditions such as diabetes or high blood pressure, severe bacterial infection is usually time limited - the patient will either get better or they will die. In either case, they do not continue to need the antibiotic. Thus, to recoup costs, the pharmaceutical company will have to sell it at low volume/high prices. Of course, if they do that, the press starts blaming them for the high cost of the medication and it is a PR disaster (see Sovaldi) even though everyone is strictly better off due to their selling the antibiotic even at a higher price. In the end, it is better for their reputation and their bottom line not to develop these antibiotics. Thus, mainly because we do not have aggressive new development of antibiotics for these severe infections, we have these articles claiming the end of the antibiotic age.
- ansible 10y agoAnd in response to that, the pharmaceutical companies will sell the antibiotic in high volumes to the livestock industry. Thus increasing profits... forever!
- loup-vaillant 10y agoWith the nice side effect that this will spur more resistances, hence more reasons to develop new drugs, that they can sell at higher prices, driving profits even upper. It's nice to get paid to solve a problem you created in the first place.
- refurb 10y agoUmmm... human and animal health are usually separate companies. I know Pfizer had an animal health unit, but it was spun off. Those are two different groups of companies you're talking about.